GCC · UAE · Distribution intelligence

Pharma Distribution Intelligence — UAE

Distrolens maps every MOHAP-licensed pharma distributor in the United Arab Emirates: who they represent, how recently their licenses were renewed, and how to reach commercial decision-makers — all from public registries and primary sources.

Coverage
MOHAP-licensed importers + 200+ specialist channels
Registrations
Drug + device registrations refreshed weekly
Freshness
License-renewal signals tracked monthly

Market context

Why UAE matters

The UAE pharmaceutical distribution market intermediates $4B+ in annual flow. Greater than 90% of imported brands route through 12 anchor distributors based in Dubai and Abu Dhabi free zones, with a long tail of specialist channels.

Primary regulator: Ministry of Health and Prevention (MOHAP)www.mohap.gov.ae

What we map

Public-source signals for UAE

  • MOHAP wholesale + manufacturing license holders
  • Brand-to-distributor authorization chains (manufacturer → UAE importer)
  • Free-zone presence: JAFZA, DAFZA, Sharjah Healthcare City, Dubai Healthcare City
  • Ownership / subsidiary edges from Wikidata + EDGAR Ex21 + corporate registries
  • Decision-maker contacts (commercial, regulatory, supply chain)
  • Tender awards from MOHAP and Emirates Health Services

Use cases

How brand owners use UAE data

Brand owner entering the UAE

You hold a manufacturing dossier and need a distributor with MOHAP relationships, free-zone storage, and a comparable therapeutic portfolio. We deliver a shortlist with portfolio overlap, license freshness, and warm-intro paths in days.

Diligence on an existing UAE distributor

Before a contract renewal — who else do they represent? Are their MOHAP licenses current? Have they been named in any sanctions or compliance signals? We deliver a one-page evidence-backed snapshot.

Tender intelligence

MOHAP and EHS tender awards mapped over time. Spot which distributors are winning what — and where the white space is.

Founder-led · Brief-form intake

Request a UAE brief

Send your therapeutic class, target launch window, and any constraints. We respond within 1 business day with scope, evidence sample, and timeline.

Start brief →
Other countries:Saudi ArabiaKenyaNigeria